Conference reports
46th Interscience Conference on Antiretroviral Agents and Chemotherapy (ICAAC), 27-30 September 2006, San Francisco
This US-based annual conference has generally reversed its trend for reduced HIV coverage, by including several important studies of new drugs.
- MK-0518 demonstrates potent efficacy in patients with triple-class resistant virus: 24 week results
- Lipid profile of integrase inhibitor MK-0518: 24 week results compared to efavirenz in treatment naive patients
- Cell studies predict cross-resistance among integrase inhibitors
- HIV may use different coreceptors in blood and brain
- Critical interactions between darunavir (TMC114), lopinavir, Viagra, and oral contraceptives
- NRTI elvucitabine active against HIV in a 7-day monotherapy study
- Efavirenz/tenofovir fails as 2-drug maintenance regimen
- Nucleoside inhibitor MK-0608 mediates suppression of HCV replication for >30 days in chronically infected chimpanzees
Links to external websites are current at time of posting but not maintained.